Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any familial isolated dilated cardiomyopathy in which the cause of the disease is a mutation in the CSRP3 gene.
Features include always present findings: Reduced left ventricular ejection fraction, Increased left ventricular end-diastolic volume, and Enlarged and weakened heart (dilated cardiomyopathy); and very common findings: Congestive heart failure. 6 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Heart and blood vessels | 6 | Endocardial fibroelastosis, Impaired myocardial contractility, Congestive heart failure |
CSRP3 encodes cysteine and glycine rich protein 3 (194 aa). Positive regulator of myogenesis. Acts as a cofactor for myogenic bHLH transcription factors such as MYOD1, and probably MYOG and MYF6. Highest expression in Heart Left Ventricle (750.4 TPM) and Heart Atrial Appendage (603.9 TPM).
Dilated cardiomyopathy 1M has limited evidence linking it to mutations in the CSRP3 gene on chromosome 11.
CSRP3 is classified as a druggable target (Transcription Factor category) with score 0.0.
Genetic testing for CSRP3 is available. Testing is considered research-grade for diagnosis.
Phenotype severity distribution: 3 always present features, 1 very common feature.
No clinical trials have been registered for dilated cardiomyopathy 1M.
6 publications have been identified in PubMed for dilated cardiomyopathy 1M. Research spans Basic Science / Preclinical (50%), Review / Meta-Analysis (17%), and Case Report / Case Series (17%).
Zhao HZ (2026). [PMID: 41688182](https://pubmed.ncbi.nlm.nih.gov/41688182/). *Zhonghua xin xue guan bing za zhi*. [Case Report / Case Series]
Vitale R (2025). [PMID: 41096706](https://pubmed.ncbi.nlm.nih.gov/41096706/). *International journal of molecular sciences*. [Basic Science / Preclinical]
Shen J (2025). [PMID: 40948388](https://pubmed.ncbi.nlm.nih.gov/40948388/). *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*. [Basic Science / Preclinical]
Bergan N (2025). [PMID: 39895490](https://pubmed.ncbi.nlm.nih.gov/39895490/). *Circulation*. [Review / Meta-Analysis]
Łuczak-Woźniak K (2024). [PMID: 39256506](https://pubmed.ncbi.nlm.nih.gov/39256506/). *Scientific reports*. [Clinical Trial Publication]
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 7:49 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Starnes L (2024). [PMID: 39041002](https://pubmed.ncbi.nlm.nih.gov/39041002/). *Frontiers in cardiovascular medicine*. [Basic Science / Preclinical]